Literature DB >> 27848224

MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases.

Kamal Dua1,2, Nicole G Hansbro3,4, Paul S Foster3,4, Philip M Hansbro5,6.   

Abstract

The rapid advancement in the area of microRNAs (miRNAs) from discovery to their translation into therapeutic moieties reflects their significance as important regulators in the management of disease pathology. The miRNAs can potentially be a new class of drugs in the near future for the treatment of various lung diseases, but it lacks the current knowledge how these identified therapeutic moieties can be designed into an effective, patient complaint and targeted drug delivery system. miRNAs have characteristic features like small size and low molecular weight which makes them easily translated into an effective drug delivery system. In this review, we have summarised the concept of miRNAs and different approaches which can be employed to deliver miRNAs effectively and safely to the target cells including the challenges associated with their development in particular emphasis on pulmonary diseases. Such approaches will be of interest for both the biological and formulation scientists to understand and explore the new vistas in the area of miRNA delivery for pulmonary inflammatory diseases.

Entities:  

Keywords:  Drug delivery; Pulmonary; miRNAs

Mesh:

Substances:

Year:  2017        PMID: 27848224     DOI: 10.1007/s13346-016-0343-6

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  95 in total

1.  A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.

Authors:  G Hutvágner; J McLachlan; A E Pasquinelli; E Bálint; T Tuschl; P D Zamore
Journal:  Science       Date:  2001-07-12       Impact factor: 47.728

2.  Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production.

Authors:  Antonie Zwiers; Laurens Kraal; Tineke C T M van de Pouw Kraan; Thomas Wurdinger; Gerd Bouma; Georg Kraal
Journal:  J Immunol       Date:  2012-01-18       Impact factor: 5.422

Review 3.  Transcription and processing of human microRNA precursors.

Authors:  Bryan R Cullen
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

4.  Antagonism of mmu-mir-106a attenuates asthma features in allergic murine model.

Authors:  Amit Sharma; Manish Kumar; Tanveer Ahmad; Ulaganathan Mabalirajan; Jyotirmoi Aich; Anurag Agrawal; Balaram Ghosh
Journal:  J Appl Physiol (1985)       Date:  2012-06-14

5.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Authors:  Ahmed Fawzy Ibrahim; Ulrike Weirauch; Maren Thomas; Arnold Grünweller; Roland K Hartmann; Achim Aigner
Journal:  Cancer Res       Date:  2011-06-20       Impact factor: 12.701

6.  Role of anti-oncomirs miR-143 and -145 in human colorectal tumors.

Authors:  Y Akao; Y Nakagawa; I Hirata; A Iio; T Itoh; K Kojima; R Nakashima; Y Kitade; T Naoe
Journal:  Cancer Gene Ther       Date:  2010-01-22       Impact factor: 5.987

7.  What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?

Authors:  Abhinav Kumar; Ben Forbes; Ian Mudway; Elif Melis Bicer; Lea Ann Dailey
Journal:  Nanomedicine (Lond)       Date:  2015-02       Impact factor: 5.307

Review 8.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery.

Authors:  Susan M van Dommelen; Pieter Vader; Samira Lakhal; S A A Kooijmans; Wouter W van Solinge; Matthew J A Wood; Raymond M Schiffelers
Journal:  J Control Release       Date:  2011-11-25       Impact factor: 9.776

9.  Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

Authors:  Amanda Tivnan; Wayne Shannon Orr; Vladimir Gubala; Robert Nooney; David E Williams; Colette McDonagh; Suzanne Prenter; Harry Harvey; Raquel Domingo-Fernández; Isabella M Bray; Olga Piskareva; Catherine Y Ng; Holger N Lode; Andrew M Davidoff; Raymond L Stallings
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

10.  Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid.

Authors:  Abhinav Kumar; Elif Melis Bicer; Anna Babin Morgan; Paul E Pfeffer; Marco Monopoli; Kenneth A Dawson; Jonny Eriksson; Katarina Edwards; Steven Lynham; Matthew Arno; Annelie F Behndig; Anders Blomberg; Graham Somers; Dave Hassall; Lea Ann Dailey; Ben Forbes; Ian S Mudway
Journal:  Nanomedicine       Date:  2016-01-06       Impact factor: 5.307

View more
  12 in total

1.  Fragmented particles containing octreotide acetate prepared by spray drying technique for dry powder inhalation.

Authors:  Ailin Hou; Lu Li; Ying Huang; Vikramjeet Singh; Chune Zhu; Xin Pan; Guilan Quan; Chuanbin Wu
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

Review 2.  Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Authors:  Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 3.  Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension.

Authors:  Chenggui Miao; Jun Chang; Guoxue Zhang
Journal:  Mol Biol Rep       Date:  2018-10-08       Impact factor: 2.316

Review 4.  The role of miRNAs in alveolar epithelial cells in emphysema.

Authors:  Hassan Hayek; Beata Kosmider; Karim Bahmed
Journal:  Biomed Pharmacother       Date:  2021-09-27       Impact factor: 7.419

5.  MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor.

Authors:  Ping Wang; Xiaomin Liu; Yang Shao; Huimin Wang; Chen Liang; Baohui Han; Zhongliang Ma
Journal:  Oncotarget       Date:  2017-06-16

6.  Nanotechnology: Advancing the translational respiratory research.

Authors:  Kamal Dua; Shakti Dhar Shukla; Terezinha de Jesus Andreoli Pinto; Philip Michael Hansbro
Journal:  Interv Med Appl Sci       Date:  2017-03

7.  miRNA nanotherapeutics: potential and challenges in respiratory disorders.

Authors:  Meenu Mehta; Dinesh K Chellappan; Peter R Wich; Nicole G Hansbro; Philip M Hansbro; Kamal Dua
Journal:  Future Med Chem       Date:  2020-04-09       Impact factor: 3.808

Review 8.  Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.

Authors:  Meenu Mehta; Devesh Tewari; Gaurav Gupta; Rajendra Awasthi; Harjeet Singh; Parijat Pandey; Dinesh Kumar Chellappan; Ridhima Wadhwa; Trudi Collet; Philip M Hansbro; S Rajesh Kumar; Lakshmi Thangavelu; Poonam Negi; Kamal Dua; Saurabh Satija
Journal:  Chem Biol Interact       Date:  2019-05-25       Impact factor: 5.192

9.  Nanoparticle delivery of microRNA-146a regulates mechanotransduction in lung macrophages and mitigates injury during mechanical ventilation.

Authors:  Christopher M Bobba; Qinqin Fei; Vasudha Shukla; Hyunwook Lee; Pragi Patel; Rachel K Putman; Carleen Spitzer; MuChun Tsai; Mark D Wewers; Robert J Lee; John W Christman; Megan N Ballinger; Samir N Ghadiali; Joshua A Englert
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

10.  Steroid resistance and concomitant respiratory infections: A challenging battle in pulmonary clinic.

Authors:  Kamal Dua; Nicole G Hansbro; Philip M Hansbro
Journal:  EXCLI J       Date:  2017-06-29       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.